Associated tags: Heart failure, Pharmacology, ALS, Muscle weakness, Mechanics, History, HCM, Cytokinetics, Patient, SAN, Pharmaceutical industry
Locations: SAN FRANCISCO, UNITED STATES, CZECH REPUBLIC, CANADA, EUROPE, UNITED KINGDOM, NEW HORIZONS, LONDON, BASELINE, SWITZERLAND, UK, SD, SOUTH SAN FRANCISCO, CA, US, PORTUGAL, SCOTLAND
FDA,
Investment,
Research,
CHMP,
Webcast,
Business,
Navigation,
Metoprolol,
Library classification,
Journal,
European Medicines Agency,
Heart failure,
Corporation,
Congress,
Obstruction,
Food,
Activate,
Conference,
Mended Hearts,
Corporate social responsibility,
ALS,
Committee,
Cardiovascular disease,
Telephone,
Safety,
Assessment,
Cytokinetics,
NYHA,
EMA,
Biology,
Clinical trial,
Ethics,
Organization,
Woman,
American College,
NDA,
MAA,
Cohort,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share. Cash, cash equivalents and investments totaled $634.3 million at March 31, 2024.
Key Points:
- Announced Topline Data from the Phase 1 Study of CK-586;
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024.
- Announced the appointment of Sung Lee to serve as the Company’s Executive Vice President, Chief Financial Officer effective as of May 8, 2024.
- Revenues for the first quarter 2024 were $0.8 million compared to $4.6 million for the corresponding period in 2023.
- Members of Cytokinetics’ senior management team will review the company’s first quarter 2024 results on a conference call today at 4:30 PM Eastern Time.
Cytokinetics,
Research,
Cardiology,
Echocardiography,
Research and development,
Patient,
Trial of the century,
Safety,
SAN,
HCM,
Pharmacokinetics,
Heart failure,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple oral doses of CK-586. The data support the advancement of CK-586 to a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which is expected to begin in Q4 2024. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of patients with HFpEF.
Key Points:
- SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586).
- The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple oral doses of CK-586.
- The data support the advancement of CK-586 to a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which is expected to begin in Q4 2024.
- No serious adverse events were observed, and the stopping criteria were not met in the study.
DSM-IV codes,
Patient,
Adolescence,
Safety,
Obstruction,
LVEF,
Risk,
Pharmacokinetics,
Cytokinetics,
NYHA,
Research and development,
Arrhythmia,
Mercury (element),
Library classification,
Heart failure,
Clinical trial,
Quality of life,
SAN,
Ageing SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.
Key Points:
- SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.
- Aficamten is a next-in-class cardiac myosin inhibitor in development for the potential treatment of HCM.
- HCM can present similarly in adolescents and children as it does in adults and may negatively impact overall quality of life.
- Patients will be randomized on a 2:1 basis to receive aficamten or placebo, and those receiving aficamten will begin with 5 mg dosed once daily.
Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance.
Key Points:
- Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance.
- Stockholders of record at the close of business on March 26, 2024 are entitled to vote at Cytokinetics’ Annual Meeting of Stockholders or to attend in person and submit questions to management.
- Stockholders wishing to vote must attend the meeting in person or submit a valid proxy card by mail, telephone or internet by 11:59 PM Eastern Time on May 14, 2024, in accordance with instructions contained in our Proxy Statement for the 2024 Annual Meeting of Stockholders.
- Interested parties may access the live webcast of the Annual Meeting of Stockholders and the subsequent presentation at the following link: Cytokinetics Annual Meeting of Stockholders.
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,646 shares of common stock and 17,012 shares of restricted stock units (RSUs) convertible into shares of common stock upon vesting to five new employees, whose employment commenced in April 2024, as a material inducement to their employment.
Key Points:
- SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,646 shares of common stock and 17,012 shares of restricted stock units (RSUs) convertible into shares of common stock upon vesting to five new employees, whose employment commenced in April 2024, as a material inducement to their employment.
- The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to the new employee’s continued service with the Company.
- Each stock option has a 10-year term.
- These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.
Retrieved on:
Wednesday, April 24, 2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time.
Key Points:
- SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time.
- Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.
- The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com .
- The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q1 2024 Earnings Conference Call.
Retrieved on:
Wednesday, April 10, 2024
School,
University,
Safety,
Patient,
Obstruction,
University of Glasgow,
Heart failure,
Cytokinetics,
Treatment,
Harvard Medical School,
SAN,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart Failure 2024, an International Congress of the European Society of Cardiology, taking place in Lisbon, Portugal from May 11, 2024 – May 14, 2024.
Key Points:
- SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart Failure 2024, an International Congress of the European Society of Cardiology, taking place in Lisbon, Portugal from May 11, 2024 – May 14, 2024.
- Title: Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM an International Multicenter Phase 3 Trial
Title: Enhancing Exercise Response in Obstructive HCM: Insights from Aficamten's Impact on Patients with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Presenter: Gregory Lewis, M.D., Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing Laboratory, Professor of Medicine, Harvard Medical School
Title: Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM
Presenter: Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of Glasgow
The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
Key Points:
- The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
- At Week 48, 75% of these patients were receiving the 15 mg or 20 mg dose of aficamten.
- Additionally, there were significant improvements in NT-proBNP, a biomarker of cardiac wall stress, with an average decrease of 63% from baseline to week 48 (p
- There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change from baseline (SD) = -5.1 mg (5.9), p
The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
Key Points:
- The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
- At Week 48, 75% of these patients were receiving the 15 mg or 20 mg dose of aficamten.
- Additionally, there were significant improvements in NT-proBNP, a biomarker of cardiac wall stress, with an average decrease of 63% from baseline to week 48 (p
- There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change from baseline (SD) = -5.1 mg (5.9), p
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment.
Key Points:
- SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment.
- The stock options that were granted are subject to an exercise price of $70.11 per share, which is equal to the closing price of the Company’s common stock on March 28, 2024, and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the subsequent 36 months, subject to the new employee’s continued service with the Company.
- Each stock option has a 10-year term and is subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.
